Brian Adams sold $1,310 of RLAY
Chief Legal Officer at Relay Therapeutics, Inc.. 299 shares at an average of $4.38, traded Dec 27, 2024, filed Dec 31, 2024.
Score components
- +15RoleOfficer
- 0Trade size$1k at market
- 0Share of holdings soldSold 0.1% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-141599, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 27, 2024 | SOpen-market sale Common Stock | -299 | $4.38 | $1,310 | 321,608 | Dec 31, 2024 |
Related signals
Other insiders at Relay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $329k 17,717 shares | -14% | |
| 36Weak | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $872k 48,199 shares | -9% | |
| 26Weak | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $162k 8,530 shares | -2% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $336k 17,717 shares | -13% | |
| 44Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $913k 48,199 shares | -8% | |
| 38Weak | Relay Therapeutics, Inc. | Brian Adams Chief Legal Officer | $73k 19,913 shares | -5% | |
| 45Moderate | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $113k 30,770 shares | -5% | |
| 45Moderate | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $74k 20,081 shares | -6% | |
| 38Weak | Relay Therapeutics, Inc. | Peter Rahmer See remarks | $63k 17,083 shares | -4% | |
| 37Weak | RLAYsell Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $219k 61,379 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.